Fox Chase Cancer Center News

Elotuzumab Promotes Unique SLAMF7-SLAMF7 Interactions That Enhance Cytotoxicity in Myeloma

PHILADELPHIA (August 20, 2019) – The immunostimulatory monoclonal antibody elotuzumab, given in combination with lenalidomide and dexamethasone, is approved for the treatment of patients with relapsed or refractory multiple myeloma. The drug binds signaling lymphocytic activation molecule family member 7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells.

VIEW STORY

Fox Chase Cancer Center Proudly Participates in the Undy RunWalk 2019

PHILADELPHIA (August 19, 2019) – Fox Chase Cancer Center will proudly participate in the Philadelphia Undy RunWalk to support the Colorectal Cancer Alliance and their mission to end colorectal cancer with national prevention, research, and patient support initiatives. Saturday, September 14, 2019, in Paine’s Park.

VIEW STORY

PARP Inhibitors Could Repair DNA in Ovarian Carcinoma Cancer Cells

PHILADELPHIA (August 16, 2019) – Recently, Fox Chase Cancer Center researchers found a potential way to sensitize a new subset of patients with high-grade serous ovarian carcinoma to PARP inhibitors, a promising drug used in some cases of this disease. Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.

VIEW STORY

Fox Chase Researchers Characterize Structure of Receptor That Helps Mediate Activity of Natural Killer Immune Cells

PHILADELPHIA (August 16, 2019) – Natural killer cells, which have an innate capacity to identify and kill tumor cells or virus-infected cells in humans, are an important part of the body’s immune system. Key in distinguishing healthy cells from abnormal cells by natural killer cells is their expression of killer cell immunoglobulin-like receptors (KIRs).

VIEW STORY

Multidisciplinary Tumor Board Coordination Increases Head and Neck Cancer Survival

PHILADELPHIA (August 14, 2019) – Patients with head and neck cancer lived longer when their treatment was coordinated by a dedicated multidisciplinary tumor board, according to a new study by clinicians at Fox Chase Cancer Center at Temple University Hospital and the Departments of Radiation Oncology and Otolaryngology-Head and Neck Surgery at the Lewis Katz School of Medicine at Temple University.

VIEW STORY

Researchers Receive Grant to Study Cell-Cell Interaction in Pancreatic Cancer

PHILADELPHIA (August 14, 2019) – Two researchers at the Fox Chase Cancer Center have received a grant to study the cell-cell communication between pancreatic cancer cells and fibroblastic stromal calls. The recipients of the National Cancer Institute grant are Igor Astsaturov, MD, PhD, an associate professor in the Department of Hematology/Oncology, and Edna Cukierman, PhD, an associate professor with the Cancer Biology Research Department.

VIEW STORY